Last reviewed · How we verify
Efavirenz QD + Zidovudine/Lamivudine BID
Efavirenz QD + Zidovudine/Lamivudine BID is a Antiretroviral combination therapy (NNRTI + 2 NRTIs) Small molecule drug developed by Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal. It is currently in Phase 3 development for HIV-1 infection.
This combination uses efavirenz (a non-nucleoside reverse transcriptase inhibitor) plus zidovudine and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking reverse transcriptase at multiple points.
This combination uses efavirenz (a non-nucleoside reverse transcriptase inhibitor) plus zidovudine and lamivudine (nucleoside reverse transcriptase inhibitors) to suppress HIV replication by blocking reverse transcriptase at multiple points. Used for HIV-1 infection.
At a glance
| Generic name | Efavirenz QD + Zidovudine/Lamivudine BID |
|---|---|
| Sponsor | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal |
| Drug class | Antiretroviral combination therapy (NNRTI + 2 NRTIs) |
| Target | HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | Phase 3 |
Mechanism of action
Efavirenz binds directly to HIV reverse transcriptase and inhibits its activity, while zidovudine and lamivudine are nucleoside analogs that are incorporated into the growing DNA chain during reverse transcription, causing chain termination. Together, these three agents provide complementary inhibition of reverse transcriptase through different mechanisms, reducing the likelihood of resistance development.
Approved indications
- HIV-1 infection
Common side effects
- Dizziness and CNS effects (efavirenz)
- Rash
- Nausea
- Anemia (zidovudine)
- Peripheral neuropathy (lamivudine/zidovudine)
- Lipodystrophy
- Hepatotoxicity
Key clinical trials
- Effects of Maraviroc vs. Efavirenz on CD4/CD8 Ratio (PHASE3)
- Trial of Maraviroc (UK-427,857) in Combination With Zidovudine/Lamivudine Versus Efavirenz in Combination With Zidovudine/Lamivudine (PHASE3)
- Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV (PHASE4)
- Safety and Effectiveness of a Combination Anti-HIV Drug Treatment (PHASE4)
- Safety and Effectiveness of TRIZIVIR (Abacavir/Lamivudine/Zidovudine) With Efavirenz in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs (PHASE4)
- A Study of the Safety and Effectiveness of Combination Anti-HIV Therapy in HIV-Infected Adults (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Efavirenz QD + Zidovudine/Lamivudine BID CI brief — competitive landscape report
- Efavirenz QD + Zidovudine/Lamivudine BID updates RSS · CI watch RSS
- Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal portfolio CI
Frequently asked questions about Efavirenz QD + Zidovudine/Lamivudine BID
What is Efavirenz QD + Zidovudine/Lamivudine BID?
How does Efavirenz QD + Zidovudine/Lamivudine BID work?
What is Efavirenz QD + Zidovudine/Lamivudine BID used for?
Who makes Efavirenz QD + Zidovudine/Lamivudine BID?
What drug class is Efavirenz QD + Zidovudine/Lamivudine BID in?
What development phase is Efavirenz QD + Zidovudine/Lamivudine BID in?
What are the side effects of Efavirenz QD + Zidovudine/Lamivudine BID?
What does Efavirenz QD + Zidovudine/Lamivudine BID target?
Related
- Drug class: All Antiretroviral combination therapy (NNRTI + 2 NRTIs) drugs
- Target: All drugs targeting HIV reverse transcriptase
- Manufacturer: Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection